|Bid||18.98 x 1300|
|Ask||19.38 x 900|
|Day's Range||18.97 - 19.01|
|52 Week Range||7.30 - 19.30|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||17.76|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
COLUMBIA, Md., April 17, 2019 -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care,.
Gainey McKenna & Egleston announces that it filed a class action lawsuit against Osiris Therapeutics, Inc. (“OSIR” or the “Company”) (OSIR) and its board of directors (the “Board”), on behalf of a proposed class consisting of all public stockholders of Osiris in connection with alleged violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) in connection with the Board’s agreement to recommend the sale of the Company to Smith & Nephew plc pursuant to the proposed tender offer by Smith & Nephew plc. As required by the federal law known as the PSLRA, this notice is being published to all stockholders of Osiris.
NEW YORK, NY / ACCESSWIRE / April 9, 2019 / Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the Southern District of New ...
According to the Centers for Medicare and Medicaid Services, healthcare spending in 2017 represented nearly 18% of U.S. GDP that year. And it projected that spending will rise 5.5% annually through 2026, when that spending will represent 20% of the country's GDP -- a boon for healthcare stocks.To put this in perspective, the U.S. defense budget is about 18% of the entire U.S. budget and we outspend every other nation on this planet in defense spending by a significant margin.The U.S. healthcare system is being debated again and may well be a significant issue in the upcoming presidential election.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut the reality is, the U.S. population is getting older and that means more chronic diseases begin to take their toll. Also, older people tend to take up a larger portion of healthcare costs as their health begins to fail. * 7 Biometric Stocks to Watch as AI Rises That means there will be an unstoppable growth trend in place for healthcare companies. The A-rated healthcare stocks I feature here are well placed to take advantage of this trend. And they're small enough that their growth will outpace their larger competitors and may make them interesting takeover targets. Healthcare Stocks: Masimo (MASI)Source: FlickrMasimo Corp (NASDAQ:MASI) is the perfect example of how technology is transforming healthcare.Once, heading the doctors or the hospital was a regular occurrence for patients with chronic issues like heart disease or diabetes. But now, monitoring technologies, where patients can wear a device that essentially tracks their functions and the data can either be downloaded remotely or by the patient and sent to the doctor, are becoming increasingly common.And MASI is one of the leaders in the field. It is also one of the two top players in the pulse oximetry sector. These are devices that check the oxygen saturation level a person's blood. Hospitals use these a great deal and generally the contracts run on a five-year basis, so income is steady and once they're in place it's unlikely the hospitals will switch over to a new type of unit, so there are solid competitive moats.MASI is up almost 59% in the past 12 months, and half of that has come in 2019. This is the kind of company that can grow with the market regardless of what U.S. healthcare ends up looking like. Ionis Pharmaceuticals (IONS)Source: Shutterstock Ionis Pharmaceuticals (NASDAQ:IONS) was founded by leading biotech scientists to expand the use of antisense therapy. It's a new form of treatment that is at the cutting edge of science medicine.Basically, if you can find a genetic marker for a disease, you can synthesize a strand of RNA that can render that gene inactive, so it doesn't reproduce. The potential uses extend to cancers, heart disease, diabetes, asthma, arthritis … the list goes on.This technology has the potential to help both rare and common maladies, many of which don't have current effective treatments. * The Elite 8 Stocks to Buy for Massive Outperformance IONS is already partnered with a number of larger pharmaceutical firms and is up 94% in the past year, with plenty of headroom left. Osiris Therapeutics (OSIR)Source: Shutterstock Osiris Therapeutics (NASDAQ:OSIR) has a market cap around $650 million, so it's in that perfect spot where it has the potential for big growth on its own, or it could be a target for takeover at a nice premium for a larger pharma looking for a unique product line.OSIR specializes in regenerative medicine products. What that means is, it uses stem cells to build medicines that help everything from wound healing to bone marrow graft acceptance. It's a unique space that has significant possibilities now and for the future.It currently has five products on the market that are focused on wound healing, ligament repairs and surgical wraps on tissues. All promote better healing outcomes with less infections than traditional methods.Last quarter it sold the rights to one of its top stem cell drug for $100 million, so it's work is being recognized. OSIR stock is up 118% for the year and 46% in 2019. Ensign Group (ENSG)Source: Shutterstock Ensign Group (NASDAQ:ENSG) specializes in post-acute care staffing for a wide variety of facilities that would need these services. Some of the most obvious would be assisted living facilities, home health care, rehab facilities and hospice. It manages 250 companies in more than 12 states, around the U.S.This is precisely the sort of sector that will be in huge demand in coming years. While all the technology and new drugs are great, there will still need to be qualified people helping support the patients as they recover and attempt to maintain active lifestyles.It continues to expand its base in California, where the company is headquartered, having just bought another company in Southern California. But its operations beyond the state show that it has what it takes to expand its model where the most opportunity is. * 10 Tech Stocks That Transformed Their Business Up 94% in the past year, its size makes it a potential takeover target or a big grower on its own. Genomic Health (GHDX)Source: Shutterstock Genomic Health (NASDAQ:GHDX) specializes in genomic diagnostic testing, specifically for cancer. The testing allows for patients and doctors to create individualized treatment strategies for patients.This is important because it means patients get the treatment they need -- they're not over-treated or under-treated. And that is good for the whole healthcare system as well as the patients.Again, this kind of diagnostic tool will be something that insurers, hospitals and patients can get behind since it allows care to better suited to each patient with the goal of lowering costs and improving outcomes.The stock is up over 112% in the past year and it's still going strong. National Research Corp (NRC)Source: Shutterstock National Research (NASDAQ:NRC) is all about delivering all the best possible outcomes for patients with their healthcare providers. NRC sees the current and future healthcare sector as patient-driven, and that is not the traditional model.The patient wasn't much more than a bundle of symptoms that were inserted into the healthcare machines to get repaired and sent back out into the world before. Now, it's about creating an experience that not only serves the patient better, but is able to deliver better outcomes and fewer return visits. It's looking at numbers that view the system more holistically.And NRC provides those numbers from its research.While it has been around since 1981, NRC is just coming into its own. And it would be a great takeover target for one of the big healthcare insurers or a large hospital chain. * 8 Genomic Testing Stocks That Can Ease the Sting of Theranos Up 30% in the past year, NRC also delivers a near-2% dividend. AngioDynamics (ANGO)Source: Flickr>AngioDynamics (NASDAQ:ANGO) is a medical device company that specializes in equipment that's used for vascular access, surgery, vascular disease and oncology. It actually made a new acquisition earlier this year to increase its oncology suite of products.Specialty medical device makers are in particular demand globally, since the good ones tend to get most of the business. Medicine is a very conservative practice and tested and true is much more preferable to new and interesting.And generally that's the view from hospitals, insurers and patients. It takes years to put new equipment in place and generally the new equipment is from a trusted equipment maker and not the kid on the block. Having been around since 1988, ANGO fits that bill.Up almost 20% in the past year, the future is bright. And its global potential is huge, as China looks to upgrade its entire healthcare system.Louis Navellier is a renowned growth investor. He is the editor of four investing newsletters: Growth Investor, Breakthrough Stocks, Accelerated Profits and Platinum Growth. His most popular service, Growth Investor, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Low-Priced Tech Stocks With Great Potential * 9 Stocks That Would Be Hurt By a Mexico/U.S. Border Closure * The Era of Car Ownership Is Over. And These 4 Charts Prove It Compare Brokers The post 7 A-Rated Healthcare Stocks for Industry Expansion appeared first on InvestorPlace.
NEW YORK , March 27, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating the proposed merger of Osiris Therapeutics, Inc. ("OSIRIS" or the "Company") ...
NEW YORK , March 22, 2019 /PRNewswire/ -- Amarin Corporation plc (AMRN) Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations that Amarin administered ...
BALA CYNWYD, PA / ACCESSWIRE / March 15, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Osiris Therapeutics, Inc. (''OSIR'' ...
NEW YORK , March 15, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Osiris Therapeutics, Inc. ("OSIR" ...
WILMINGTON, Del., March 14, 2019 -- Rigrodsky & Long, P.A.: Do you own shares of Osiris Therapeutics, Inc. (NASDAQ GM: OSIR)? Did you purchase any of your shares prior to.
NEW YORK , March 13, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...
NEW YORK , March 12, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Osiris Therapeutics, Inc. (NASDAQ: OSIR) and its board of directors for breach of fiduciary duty concerning ...
NEW YORK, March 12, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Osiris Therapeutics, Inc. (“Osiris”.
Columbia-based Osiris is coming off a tumultuous three-year period in which four CEOs left the company and several former executives faced criminal charges for fraud.
Do you own shares of Osiris Therapeutics, Inc. (NASDAQ GM: OSIR)? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Osiris Therapeutics, Inc. (“Osiris” or the “Company”) (NASDAQ GM: OSIR) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Smith & Nephew plc (“Smith & Nephew”) (NYSE: SNN) in a transaction valued at approximately $660.5 million.
The deal will help Smith & Nephew better compete with bigger rivals such as U.S.-based Johnson & Johnson as Osiris's products, including skin and bone grafts, complements its portfolio of wound care products. "Greater presence in the fast growing regenerative medicine market enhances our portfolio and will help immediately accelerate our wound management business," Smith & Nephew Chief Executive Officer Namal Nawana said.
Smith & Nephew Plc said on Tuesday it would buy U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million, as the British medical products maker looks to bulk up in an area that is quickly growing. The deal will help Smith & Nephew better compete with bigger rivals such as U.S.-based Johnson & Johnson as Osiris's products, including skin and bone grafts, complements its portfolio of wound care products. "Greater presence in the fast growing regenerative medicine market enhances our portfolio and will help immediately accelerate our wound management business," Smith & Nephew Chief Executive Officer Namal Nawana said.
British medical products maker Smith & Nephew Plc said on Tuesday it would buy U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million, as it looks to boost profit margins and find ...
Osiris Therapeutics, Inc. (OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today announced that it has entered into an agreement and plan of merger with Smith & Nephew plc pursuant to which Smith & Nephew will acquire Osiris for $19.00 per share in cash, a total of approximately $660.5 million in cash. Peter Friedli, Chairman of the Board and co-founder of Osiris, said, “This is a very good outcome for Osiris’ shareholders.
Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Jay M. Moyes has been named to the company’s Board as an independent director, effective immediately. Moyes brings more than 30 years of healthcare industry expertise in senior-level financial positions and has significant governance experience from Board memberships at publicly traded healthcare companies. “We are delighted to attract a professional of Jay’s caliber as we build out Predictive’s Board with proven leaders to support our strategy of bringing proprietary genetic-based diagnostics and therapeutics to market,” said Bradley C. Robinson, CEO of Predictive Technology Group.
Troubled Atlanta biomedical company MiMedx Group Inc. (OTC: MDXG) is being sued by competitor Osiris Therapeutics Inc. (Nasdaq: OSIR), who claims MiMedx "jeopardized Osiris’s business by deceit, trickery, and unfair methods." In a complaint filed Feb. 20 in federal court in Atlanta, Columbia, Md.-based Osiris contends MiMedx and a distributor it formerly owned, Stability Biologics, breached several obligations they owed to Osiris, which had been a customer of Stability before it was bought by MiMedx in January 2016. Osiris and MiMedx are direct competitors in the market for regenerative cellular and tissue-based products used to treat injuries and wounds.
National investor-rights law firm Hagens Berman Sobol Shapiro LLP reached an $18.5 million settlement on behalf of investors in Osiris Therapeutics, Inc. who purchased shares between May 12, 2014 and November 16, 2015.
National investor-rights law firm Hagens Berman Sobol Shapiro LLP reached a settlement on behalf of investors in Osiris Therapeutics, Inc. who purchased shares between May 12, 2014 and November 16, 2015.
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]